Ironwood Pharmaceuticals Inc IRWD:NASDAQ

Last Price$8.70NASDAQ Previous Close - Last Trade as of 3:59PM ET 10/14/19

Today's Change-0.11(1.25%)
Bid (Size)$8.69 (134)
Ask (Size)$8.70 (167)
Day Low / High$8.57 - 8.82
Volume621.7 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 10/14/2019

 

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $8.70
Change: -0.11 (1.25%)
Volume: 621.7 K
3:59PM ET 10/14/2019
 
 

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $25.19
Change: -0.68 (2.61%)
Volume: 415.9 K
4:00PM ET 10/14/2019
 
 

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $84.28
Change: -2.85 (3.27%)
Volume: 91.8 K
4:00PM ET 10/14/2019
 
 

Pacira Biosciences Inc ( NASDAQ )

Price: $36.61
Change: -1.08 (2.87%)
Volume: 332.1 K
4:00PM ET 10/14/2019
 
 

Corcept Therapeutics Inc ( NASDAQ )

Price: $14.05
Change: -0.05 (0.35%)
Volume: 510.2 K
4:00PM ET 10/14/2019
 

Read more news Recent News

Ironwood Pharmaceuticals, AstraZeneca Amend Terms of Linzess Deal in China
5:03AM ET 9/18/2019 MT Newswires

Ironwood Pharmaceuticals (IRWD) said Wednesday it has amended its collaboration agreement with AstraZeneca (AZN) for Linzess, an irritable bowel syndrome...

Ironwood Pharmaceuticals' 2019, 2020 Full Year Earnings Estimates Ratcheted Up
2:46AM ET 8/20/2019 MT Newswires

The full year forecasted earnings estimates for 2019 and 2020 for Ironwood Pharmaceuticals Inc (NASDAQ:IRWD, Recent Price: 8.98) have been raised. The...

2020 Earnings Projection for Ironwood Pharmaceuticals Increased
1:41AM ET 8/17/2019 MT Newswires

Ironwood Pharmaceuticals Inc's (NASDAQ:IRWD, Recent Price: 8.77) 2020 forecasted earnings estimate for the year ending December 31, 2020 has been scaled...

Ironwood Pharma to Promote Alnylam's Givosiran for Genetic Disease AHP - IRWD Rises 5%
3:07PM ET 8/13/2019 MT Newswires

Alnylam Pharmaceuticals (ALNY) and Ironwood Pharmaceuticals (IRWD) said on Tuesday they have agreed to a deal for Ironwood to provide Acute Hepatic...

Company Profile

Business DescriptionIronwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller in 1998 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Phone+1.617.621.7722
Number of Employees515
Recent SEC Filing09/18/20198-K
Chief Executive Officer & DirectorMark Mallon
PresidentThomas A. McCourt
Chief Financial Officer & Senior Vice PresidentGina R. Consylman
Chief Medical Officer & Senior Vice PresidentMichael Shetzline

Company Highlights

Price Open$8.78
Previous Close$8.70
52 Week Range$7.91 - 17.70
Market Capitalization$1.4 B
Shares Outstanding156.5 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement11/05/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.93
Beta vs. S&P 500N/A
Revenue$346.6 M
Net Profit Margin-64.48%
Return on Equity111.43%

Analyst Ratings as of 09/05/2019

Buy
3
Overweight
0
Hold
5
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset